As Provenge Sales Dip, Dendreon Hopes Restructuring Is The Answer
This article was originally published in The Pink Sheet Daily
Despite weaker sales of the cancer immunotherapy compared to the first quarter, the Seattle-based biotech insists it can stimulate demand.
You may also be interested in...
Medicare’s decision to initiate a formal review of coverage for the newly approved Alzheimer’s agent is a highly unsettling development in many respects. It is also probably the best possible news for Biogen and Eisai at this point.
The once-hot biotech finally has filed for bankruptcy as it does its best to pay back note holders and looks to sell its floundering prostate cancer therapy in an effort to honor remaining employee contracts.
The early successes enjoyed by new autologous, cell-based cancer therapies, as well as new advances in gene therapy and regenerative medicine, have reignited interest at Big Pharma in these advanced treatments, said partnering executives at the recent Therapeutic Area Partnerships meeting in Boston.